Kanavel's SignsMANAGEMENT

SYSTEMIC AND MISCELLANEOUS PRESENTATIONS · 12 SECTIONS

⚲

565 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

Allergic Transfusion Reaction Anaphylaxis Angioedema Benedikt's Syndrome Cannabis-induced hyperemesis Eczema (acute flare)Gradenigo's Syndrome Horner's Syndrome (Acute)Huntington's Disease (Acute Presentation)Kanavel's Signs Lemierre's Syndrome Procedural sedation Radiation exposure Retained products of conception Sever's Disease Urticaria Venous air embolism

01Approach to the Critical Patient/attcp38

Immediate priorities

›Surgical emergency recognition

›Pyogenic flexor tenosynovitis (PFT) is a closed-space infection requiring emergent surgical consultation

›Delay beyond 24 to 48 hours significantly worsens outcomes

›Digital ischemia or subcutaneous purulence indicates high amputation risk

›Sepsis screening in all suspected PFT

›Fever, tachycardia, hypotension, or altered mental status

›Systemic signs mandate IV access, blood cultures, and early antibiotics

›If digital ischemia present, orthopedic or hand surgery consult immediately

›Stage III disease carries 59% amputation rate

›Vascular surgery co-consultation if perfusion compromised

Key assessment

›Kanavel signs assessment at bedside

›Fusiform (sausage) swelling of the entire digit

›Symmetric circumferential swelling distinguishes PFT from felon

›Involves entire length of finger including proximal segment

›Flexed resting posture of the affected digit

›Physiologic response to sheath pressure

›Involuntary semiflexed position

›Pain with passive extension

›Most sensitive and earliest sign

›Even gentle extension of the digit triggers pain

›Tenderness along the flexor tendon sheath

›Volar midline from A1 pulley to DIP joint

›Differentiates from joint-line tenderness of septic arthritis

›Proximal spread evaluation

›Horseshoe abscess pattern

›Thumb radial bursa communicates with ulnar bursa of small finger via Parona's space

02History/hx49

Mechanism and timeline

›Penetrating trauma to the volar digit

›Thorn prick, puncture wound, laceration

›Most common inoculating mechanism

›Agricultural workers and food handlers at higher risk

›Animal or human bites

›Animal bites: Pasteurella multocida

›Human bites or clenched-fist injuries: Eikenella corrodens

›IV drug use

›Hematogenous seeding of tendon sheath

›Broader gram-negative organism coverage required

›Symptom onset and progression

›Symptom onset typically 2 to 5 days after inoculating event

›Rapidly worsening pain and swelling

›Progressive inability to flex or extend the finger

›Absence of a clear wound does not exclude PFT

›Hematogenous spread possible

›Occult inoculation sites common

Risk factors

›Comorbidities associated with worse outcomes

›Diabetes mellitus

›Higher amputation rates

›Impaired immune response

›Peripheral vascular disease

›Digital ischemia risk amplified

›Poor wound healing

›Renal failure

›Antibiotic dosing adjustment required

03Physical Exam/exam52

Kanavel signs

›Fusiform swelling

›Inspect for symmetric circumferential swelling of entire digit

›Differentiates from felon (distal pulp only)

›Differentiates from paronychia (nail fold only)

›Sausage finger appearance

›Erythema and warmth may accompany swelling

›Flexed resting posture

›Digit held in partial flexion at rest

›Compare to contralateral hand

›Involuntary posturing due to sheath pressure

›Pain with passive extension

›Gently extend digit through full range

›Most sensitive sign of PFT

›Disproportionate pain response

›Avoid forceful manipulation

›Flexor sheath tenderness

›Palpate volar surface from A1 pulley to DIP

›Tenderness along entire sheath course is characteristic

›Joint-line tenderness alone suggests septic arthritis

Vascular and perfusion assessment

›Digital perfusion examination

›Capillary refill time of affected digit

›Prolonged refill suggests ischemia

›Compare to adjacent digits

›Color and temperature assessment

›Dusky, pale, or mottled digit indicates vascular compromise

›Stage III PFT with ischemia carries 59% amputation rate

04Differential Diagnosis/ddx53

Life-threatening and surgical mimics

›Necrotizing fasciitis of the hand

›ICD-10 M72.6

›Rapidly spreading tissue death

›Crepitus, skin necrosis, systemic toxicity

›Surgical emergency with higher mortality than PFT

›Extensive debridement required

›Deep space abscess

›Thenar space abscess

›Swelling of thenar eminence with preserved thumb flexion

›Midpalmar space abscess

›Middle or ring finger dorsal and palmar fullness

›Web space abscess

›Interdigital space swelling

Close mimics

›Felon

›ICD-10 L03.01

›Distal pulp space abscess

›Pain and swelling localized to fingertip only

›Kanavel signs absent

›Sheath tenderness does not extend proximally

›Cellulitis without PFT

›ICD-10 L03.011

›Diffuse erythema without specific Kanavel signs

›Inflammatory markers (CRP, WBC) paradoxically more elevated in cellulitis than early PFT

›No fusiform swelling or resting flexion

›Septic arthritis DIP or PIP joint

›ICD-10 M00.9

05Laboratory Tests/lt36

Infection markers

›Complete blood count

›Leukocytosis may support infection but often normal in early or isolated PFT

›Inflammatory markers paradoxically lower in PFT than cellulitis

›Normal WBC does not exclude PFT

›Lymphopenia as immunocompromise marker

›CRP and ESR

›May be normal early in isolated PFT

›CRP and ESR more reliably elevated in cellulitis than early PFT

›Serial trending more useful than single value

›Elevated ESR and CRP support systemic infection

›Procalcitonin

›Elevated with systemic bacteremia or sepsis

›Limited specificity for isolated digit infection

›Useful if hematogenous seeding suspected

Metabolic and organ function

›Basic metabolic panel

›Renal function for antibiotic dosing

›Vancomycin and aminoglycoside adjustment required

›CKD worsens prognosis

›Glucose and HbA1c

›Undiagnosed diabetes screening

›Hyperglycemia associated with worse outcomes

›Blood cultures

›When febrile or systemically ill

›Prior to antibiotics when feasible without delaying treatment

›Positive in hematogenous PFT cases

›MRSA is most common organism in many series

06Diagnostic Tests/dt69

Scoring Systems

›Pang classification system for PFT prognosis

›Stage I

›No subcutaneous purulence

›No digital ischemia

›Best prognosis with surgical drainage

›Stage II

›Subcutaneous purulence present

›No digital ischemia

›8% amputation rate

›Stage III

›Subcutaneous purulence present

›Digital ischemia present

›59% amputation rate

›Kanavel sign aggregate assessment

›No validated scoring system exists

›Aggregate number of signs increases diagnostic confidence

›All 4 signs present in only 34% of confirmed cases

›At least 3 signs present in 62% of confirmed cases

›Clinical gestalt combined with signs guides decision

›Surgical consultation when 2 or more signs present

MRI

›MRI hand and wrist role

›Problem-solving in diagnostically uncertain cases

›Differentiates PFT from cellulitis and septic arthritis

›Detects sheath fluid and tenosynovial enhancement

›Sesamoiditis differentiation from PFT

›Bone marrow edema pattern on MRI

07Disposition/dispo33

Surgical admission indications

›All confirmed or strongly suspected PFT require hospital admission

›IV antibiotics and surgical drainage cannot be managed outpatient

›Oral antibiotics alone are insufficient for established PFT

›Hand surgery or orthopedic surgery consultation for operative drainage

›Surgical irrigation timing

›Open sheath irrigation and debridement within hours of diagnosis

›Continuous postoperative irrigation catheter technique used in some centers

›ICU or step-down indications

›Septic shock or hemodynamic instability

›Vasopressor requirement

›Organ dysfunction from systemic infection

›Necrotizing fasciitis with systemic toxicity

›Intensive monitoring post-debridement

›Immunocompromised host with atypical organism

›Close monitoring for rapid deterioration

Discharge criteria

›Discharge not appropriate until surgical drainage completed

›Post-operative discharge criteria

›Wound healing without signs of ongoing infection

›Tolerating oral antibiotics

›Adequate hand therapy and rehab plan in place

›Early very mild PFT without purulence

›Selected cases managed with IV antibiotics and close surgical observation

›Only when all 4 signs not present and presentation very early

›Requires 24 to 48 hour inpatient observation minimum

Follow up

›Post-discharge follow up requirements

08Treatment/t69

Immediate antibiotics

›Empiric IV antibiotic initiation upon clinical suspicion

›Do not delay antibiotics for surgical consultation

›Class I recommendation by expert consensus

›Standard empiric coverage

›Cefazolin IV 1 to 2 g every 8 hours for MSSA coverage

›Adjust dose for renal function

›Add vancomycin for MRSA coverage

›Vancomycin IV 15 to 20 mg per kg every 8 to 12 hours

›AUC-guided monitoring preferred over trough alone

›Target AUC 400 to 600 mg-h per L

›Ampicillin-sulbactam IV 3 g every 6 hours as alternative

›Covers MSSA, gram-negatives, and anaerobes

›Add vancomycin if MRSA risk present

›Bite wound coverage

›Animal bites: add ampicillin-sulbactam or piperacillin-tazobactam

›Piperacillin-tazobactam IV 4.5 g every 6 hours

›Pasteurella multocida coverage

›Renal dose adjustment required

›Human bites: ampicillin-sulbactam covers Eikenella corrodens

›Ampicillin-sulbactam IV 3 g every 6 hours

›IV drug use coverage

›Broader gram-negative coverage required

›Piperacillin-tazobactam IV 4.5 g every 6 hours

›Plus vancomycin for MRSA

›Consider Pseudomonas coverage in severe or systemic cases

Surgical intervention

›Surgical drainage is the definitive treatment

›Open flexor sheath irrigation and debridement

›Most definitive technique for established purulence

›Allows direct visualization of tendon viability

›Catheter-based closed continuous irrigation technique

›Intraoperative placement of irrigation catheter in sheath

›Post-operative continuous saline irrigation for 24 to 48 hours

›May reduce adhesion formation compared to open drainage

›Tendon viability assessment during surgery

›Non-viable tendon requires debridement

›Staged reconstruction if extensive involvement

›Amputation indications

›Digital ischemia with non-viable digit

›Stage III PFT with irreversible vascular compromise

›59% amputation rate in Stage III disease

›Extensive tendon necrosis

›Functional reconstruction not feasible

Adjunct treatments

›Tetanus prophylaxis

›If wound-related and tetanus status not up to date

›Tetanus toxoid 0.5 mL IM if primary series completed but booster due

›Tetanus immunoglobulin 250 units IM if no prior immunization

›Analgesia

›Acetaminophen 500 to 1000 mg PO or IV every 6 hours

›First-line non-opioid analgesia

›NSAIDs with caution

›Avoid masking progression of infection symptoms

›Renal function assessment required

›Opioid analgesia for severe pain

›Short course only

›Regional nerve block consideration by anesthesia

›NPO status

›Maintain NPO anticipating surgical drainage

›Oral intake restricted once surgical plan initiated

Antibiotic duration and de-escalation

›Duration of therapy guided by intraoperative cultures

›Uncomplicated PFT with complete surgical drainage

›7 to 14 days total antibiotics typical

›De-escalate to oral agents once afebrile and clinically improving

›MRSA confirmed infection

›Continue vancomycin until clinically improved

›Transition to trimethoprim-sulfamethoxazole 1 to 2 DS tablets PO twice daily

›Or doxycycline 100 mg PO twice daily for MRSA soft tissue infection

›Complicated cases with osteomyelitis or bursal involvement

›4 to 6 weeks of antibiotic therapy

›Infectious disease guidance recommended

09Special Populations/sp59

Pregnancy

›Pregnancy considerations for PFT

›Surgical drainage remains indicated regardless of gestational age

›Untreated PFT poses greater risk than anesthesia and surgery

›Obstetric consultation for perioperative fetal monitoring

›Antibiotic selection in pregnancy

›Beta-lactams preferred: cefazolin or ampicillin-sulbactam

›Category B safety profile

›No teratogenicity demonstrated

›Vancomycin use when MRSA suspected

›Monitor for nephrotoxicity given renal changes in pregnancy

›Avoid tetracyclines

›Fetal bone and tooth development effects

›Avoid trimethoprim-sulfamethoxazole especially first trimester and near term

›Folate antagonism and neonatal kernicterus risk

›Anesthesia considerations

›Regional anesthesia preferred over general when feasible

›Airway changes of pregnancy increase intubation risk

›Fetal monitoring perioperatively if viable gestation

›Coordinate with obstetrics for monitoring protocols

Geriatric

›Older adult PFT features

›Atypical or blunted presentation

›Afebrile despite infection

›Reduced Kanavel sign expressivity in longstanding diabetes or peripheral neuropathy

›Higher comorbidity burden

›Diabetes, PVD, and CKD more prevalent in older patients

›All associated with worse PFT outcomes including higher amputation rates

10Background/b63

Epidemiology

›Incidence and population data

›PFT represents 2.5% to 9.4% of all hand infections

›Common emergency hand surgery condition

›Year-round incidence without seasonal pattern

›Most commonly affected digits

›Index and middle fingers most frequently involved

›Thumb involvement carries bursal spread risk

›Peak age of incidence

›30 to 50 years of age most common

›Age greater than 43 years associated with worse prognosis

›Organism distribution

›Staphylococcus aureus most common overall

›MRSA most common in many contemporary series

›Bite wounds: Pasteurella multocida and Eikenella corrodens

›IV drug use: gram-negative organisms including Pseudomonas

›Outcomes data

›Overall amputation rate approximately 5% to 10% in reported series

›Stage III (ischemic) PFT 59% amputation rate

›Delayed presentation beyond 48 hours worsens prognosis

›Functional impairment common even with successful digit salvage

›Tendon adhesions limiting range of motion

›Prolonged hand therapy required

Pathophysiology

›Anatomy of the flexor tendon sheath

›Closed-space synovial sheath enveloping flexor digitorum profundus and superficialis tendons

›Runs from A1 pulley at MCP level to DIP joint insertion

›Contained space allows rapid pressure build-up with infection

11Patient Discharge Instructions/pdi25

copy discharge instructions

›Home care after finger tendon sheath infection (flexor tenosynovitis)

›Complete the full course of prescribed antibiotics

›Do not stop early even if feeling better

›Keep the hand elevated above heart level to reduce swelling

›Use a sling or pillow when resting

›Wound care as directed by your surgeon

›Keep dressing clean and dry unless instructed otherwise

›Attend all hand therapy appointments

›Gentle range-of-motion exercises are critical to prevent stiffness

›Warning signs requiring return to emergency

›Increasing pain, swelling, or redness in the finger or hand

›Fever above 38.5 degrees Celsius

›Finger turning pale, blue, or cold

›Numbness or loss of feeling in the finger

›Wound drainage increasing or becoming foul smelling

›Inability to move the finger that was previously improving

›New pain spreading into the wrist or palm

›Follow up instructions

›Hand surgery or orthopedic clinic within 24 to 48 hours of discharge

›Occupational therapy or hand therapy referral as arranged

›Infectious disease follow up if prescribed extended antibiotics

›Activity and return to work

›No heavy lifting or gripping with the affected hand until cleared by surgeon

›Return to work timeline depends on hand function recovery

›Protective gloves recommended once cleared for manual tasks

12References/r19

Guidelines and key sources

›Foundational and guideline references

›Kanavel AB original description of flexor tenosynovitis signs published 1912

›Classic four cardinal signs remain standard teaching

›Current literature on PFT management

›Pang HN et al classification system for PFT prognosis (Stages I, II, III)

›MRSA predominance in contemporary PFT series

›American Society for Surgery of the Hand guidelines

›Surgical management recommendations for flexor tenosynovitis

›Diagnostic and prognostic evidence

›Studies showing only 34% of PFT cases present with all 4 Kanavel signs

›Clinical aggregate approach rather than requiring all signs

›Radiographic criterion: 7 mm soft tissue thickness difference at proximal phalanx

›PPV of 82% for PFT diagnosis

›Point-of-care ultrasound emerging evidence for sheath fluid detection

›Coding references

›ICD-10 M65.04 pyogenic flexor tenosynovitis of finger

›SNOMED CT pyogenic flexor tenosynovitis disorder

›ICD-10 L03.01 cellulitis of finger as key differential code

›ICD-10 M65.0 abscess of tendon sheath

Learn More: Kanavel's Signs→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.